A novel eye drop of 2.6% EDTA ophthalmic solution (C-KAD, Livionex) showed significant and consistent improvement in visual quality and function in patients with early-stage cataract, according to US researchers.
Writing in the American Journal of Ophthalmology, researchers at the University of Utah conducted the phase 1/2 clinical trial of 41 subjects, who were given C-KAD (n=21) or placebo (n=20). The primary endpoint of the proportion of eyes with mesopic contrast sensitivity (CS) improvements ≥ 0.30 logCS (equivalent to 100% CS improvement) in at least two of the five spatial frequencies was significantly greater for C-KAD (66.7% vs. 35.0% for placebo, p=0.043) at day 120, they said. “The proportion of eyes achieving ≥ 0.30 logCS improvement (mesopic) was also significantly greater for C-KAD, with 42.9% compared to 15.0% for placebo (p=0.050) at day 120. Positive best-corrected visual acuity trends and statistical significance in lens density were also observed.”
